PROKIDNEY CORP.

ProKidney Corp. (Nasdaq: PROK) is a clinical-stage biopharmaceutical company focused on developing cell-based therapies for chronic kidney disease, with its lead program targeting patients with type 2 diabetes-related renal decline. The company went public through a business combination with Social Capital Suvretta Holdings Corp. IV, a blank-check company sponsored by Social Capital Suvretta, completing its de-SPAC merger in 2023. ProKidney filed a DEFA14A — supplemental definitive proxy materials — with the SEC on April 17, 2026, indicating an active shareholder vote process is underway. The company operates in the biotechnology and regenerative medicine sector. Visit SpacDesk and sign up for full data, filings history, and real-time alerts on PROK and hundreds of other SPAC-origin companies.